TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03226145

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Motility
Description: MRI sequence to assess colonic motility

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Motility
Description: MRI sequence to assess colonic motility

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Resolution Manometry
Description: HRM of colon to assess motility

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Resolution Manometry
Description: HRM of colon to assess motility

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl
Description: Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine butylbromide
Description: Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
Study: NCT01365039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test, daily disposable contact lens
Description: Test lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SofLens daily disposable contact lens
Description: Control lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
Study: NCT01203540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAABAK eyedrops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline eyedrops
Study: NCT01505348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overnight fast
Description: Overnight fast from 21:00 h
Study: NCT00129766

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: motavizumab (MEDI-524)
Description: Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: palivizumab
Description: Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
Study: NCT01337856

Intervention type: OTHER
Group type: OTHER
Intervention: Hand hygiene protocol
Description: Comparison of efficacy of 3 hand hygiene protocols

Intervention type: OTHER
Group type: OTHER
Intervention: Hand hygiene protocol
Description: Comparison of efficacy of 3 hand hygiene protocols

Intervention type: OTHER
Group type: OTHER
Intervention: Hand hygiene protocol
Description: Comparison of efficacy of 3 hand hygiene protocols
Study: NCT04636827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV+DTaP+HepA
Description: sIPV+DTaP+HepA at the age of 18 month old

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sIPV
Description: sIPV at the age of 18 month old

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP
Description: DTaP at the age of 18 month old

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HepA
Description: HepA at the age of 18 month old
Study: NCT01035099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole titrated regimen may be started on day 2 of menstrual cycle:~Serum Estradiol level \<150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level \>350 pg/ml - 7.5 mg;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle
Study: NCT03411720

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FES Row Training
Description: Hybrid FES Row Training using voluntary upper body and electrically-stimulated lower body

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES Row Training
Description: Hybrid FES Row Training using voluntary upper body and electrically-stimulated lower body

Intervention type: OTHER
Group type: OTHER
Intervention: FES Row Training
Description: Hybrid FES Row Training using voluntary upper body and electrically-stimulated lower body
Study: NCT01361035

Intervention type: OTHER
Group type: OTHER
Intervention: Cancer risk communication skills training
Description: Intervention physicians receive training in cancer risk communication and shared decision making (SDM). At the end of each visit with intervention physicians, standardized patients (SPs) reveal themselves as actors and give structured verbal feedback. After baseline SP visits, each intervention physician undergoes academic detailing with a communication expert. Intervention physicians are directed to a web-based communication skills tutorial where SP ratings are hyperlinked to key references for supplemental reading. Both study groups will receive annual reports detailing their patients' cancer screening status and aggregate ratings of their communication style.
Study: NCT02938884

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HidrateSpark Water Bottle
Description: HidrateSpark water bottle is a smart water bottle that glow when its time to drink water. It is run through an app on a smart phone
Study: NCT00933673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asp, DXM, IFO, VP-16, DDP
Description: L-asp 6000 u/m2; DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 60 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
Study: NCT05015075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cardiac rehabilitation
Description: cardiac rehabilitation after pacemaker implantation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cardiac rehabilitation
Description: cardiac rehabilitation after pacemaker implantation
Study: NCT01590940

Intervention type: PROCEDURE
Intervention: Open inguinal hernia repair with mesh
Study: NCT02605187

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No choice given
Description: Patients are randomized to getting a choice or not getting a choice. If they do not get a choice, they receive standard dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choice given
Description: Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choice given
Description: Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choice given
Description: Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 600mg po q6h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 600mg po q6h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 600mg po q6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 600mg po q6h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 650mg po q6h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 650mg po q6h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 650mg po q6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 650mg po q6h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 600mg po one time within 1 hour of delivery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine (low)
Description: Intrathecal morphine dose 50mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine (med)
Description: Intrathecal morphine dose 150mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine (med)
Description: Intrathecal morphine dose 150mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine (high)
Description: Intrathecal morphine 300mcg
Study: NCT02640833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Duvelisib will be taken continuously. This is a defining dose study, therefore the dose of Duvelisib may change.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be taken continuously. This is a defining dose study, therefore the dose of Venetoclax will change.
Study: NCT01841411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole + N-Acetyl cysteine
Description: Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement, It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has antibacterial and antibiofilm activities

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis in treatment of bacterial vaginosis, it can be used in treatment of bacterial vaginosis either in a dose of 500 mg twice daily or 250 mg three times daily for seven days
Study: NCT03364244

Intervention type: DRUG
Intervention: Sildenafil
Description: \[REVATIO® Tablets / REVATIO® OD Film\] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily.~\[REVATIO® Dry Syrup for Suspension\] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 8 kg or more but less than 20 kg: Usually, sildenafil 10 mg is orally given three times daily.~In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily.
Study: NCT01476475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine /lixisenatide Fixed Ratio Combination
Description: FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using pen-type injector (Tactipen®): 100 U/ml insulin glargine and 50 mcg Lixisenatide (ratio of 2 U/1 mcg). The initial dose was 10 U/5 mcg and then dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine (100 U/ml) was self-administered by SC injection before breakfast using pen-type injector (Lantus® Solostar®). The initial daily dose of insulin glargine was 10 U and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin (Background drug)
Description: Pharmaceutical form: Tablet; Route of administration: oral administration. To be kept at stable dose (≥1.5 g/day) throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (Background drug)
Description: Pharmaceutical form: Tablet; Route of administration: oral administration. To be kept at stable dose (≥1.5 g/day) throughout the study.
Study: NCT01667770

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: decompression of Chiari malformation
Description: Removal of a small section of bone at the back of the skull (posterior foramen magnum decompression) or upper cervical spine. During surgery, the covering of the brain (dura) is enlarged with a graft (autologous or non-autologous).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: decompression of Chiari malformation
Description: Removal of a small section of bone at the back of the skull (posterior foramen magnum decompression) or upper cervical spine. During surgery, the covering of the brain (dura) is enlarged with a graft (autologous or non-autologous).
Study: NCT01908764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-60371 otic suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-60371 otic suspension
Study: NCT03381235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spin exercise
Description: Each exercise class will consist of 20 minutes of progressive, interval based Spin exercise 2 times a week for 6 months on stationary exercise cycles and will be led by a qualified instructor. The Duration of each session is lengthened based on the progression of the participant and the recommendation of the instructor by 1-2 minutes as needed to a maximum time of 60 minutes per session. Exercise intensity will begin at low levels (50% of maximal heart rate reserve (HRR) and increase by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
Study: NCT00843388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolacton (hexalacton(R))
Description: Tablet Spironolacton 25 mg OD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: placebo tablet 25 mg OD
Study: NCT04417634

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RFR
Description: Measurement of resting flow ratio

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FFR
Description: Measurement of fractional flow reserve
Study: NCT01816061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental - COMPASS
Description: Controlled randomized clinical trial. Fifty-five participants in the intervention group will receive eight goal self-management sessions over a period of approximately ten weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control - COMPASS
Description: Increased hours of patient-provider interactions Group.
Study: NCT01086020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 10mg/d for two years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin plus ezetimibe
Description: Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d for two years
Study: NCT03070470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine 1500 mg orally two times per day for 2.5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / Ritonavir
Description: Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (administered orally)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dofetilide and Diltiazem
Description: In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.
Study: NCT02589899

Intervention type: OTHER
Intervention: Needle placement in different tissue types
Description: Bioimpedance will be measured for needle positions in different tissue types
Study: NCT01671111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184AQ
Description: Long term extension study of 8-75 mg/kg/d of SSP-004184AQ (equivalent to 7-68 mg/kg/d free acid or active form)
Study: NCT02801656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Oral, encapsulated FMT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin po 125 mg qid x 10 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation Placebo
Description: Matching placebo to FMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Placebo
Description: Matching placebo to Vancomycin
Study: NCT04503304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: already included in arm/group descriptions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: already included in arm/group descriptions.
Study: NCT00530270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Individuals meeting entry criteria will be randomized to receive dexamethasone 0.3 mg/kg (12 mg maximum single dose). The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individuals meeting entry criteria will be randomized to receive 0.3 mg/kg (12 mg maximum single dose) of placebo. The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
Study: NCT01989312

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous cannulation.
Description: A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular block and ultrasound-guided ulnar, median and radial nerve blocks.
Description: Supraclavicular block with 20 mL of lidocaine 1.5% + epinephrine 5µg/mL and the addition of ultrasound-guided ulnar, median and radial nerve blocks. For that 12 mL of local anesthetic solution of a 50:50 mixture of lidocaine 2% and levobupivacaine 0.5% (4 mL/nerve) was used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous cannulation.
Description: A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous cannulation.
Description: A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine ASA monitoring
Description: Monitorization with ECG, noninvasive blood pressure and spO2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine ASA monitoring
Description: Monitorization with ECG, noninvasive blood pressure and spO2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premedication midazolam
Description: Premedication with 0.03 mg/kg midazolam iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premedication midazolam
Description: Premedication with 0.03 mg/kg midazolam iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Study: NCT03863600

Intervention type: BEHAVIORAL
Intervention: Midwife-led continuity of care
Description: Midwives from governmental hospitals provide antenatal and postnatal case-load-care in rural villages governmental clinics
Study: NCT04384562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: A 20 mg methylphenidate (Ritalin®) is administered only once for the dopamine reuptake inhibitor group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reboxetine
Description: A 4 mg reboxetine (Edronax®) is administered only once for the noradrenaline reuptake inhibitor group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: A 2 mg nicotine (Nicorette®) gum is administered only once for the cholinergic receptor agonist group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill
Description: A placebo pill is administered only once.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: A placebo pill is administered only once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo gum
Description: A placebo gum is administered only once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo gum
Description: A placebo gum is administered only once.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gum
Description: A placebo gum is administered only once.
Study: NCT04142775

Intervention type: OTHER
Intervention: complication versus no complication
Description: development of ICH
Study: NCT03589599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored tobacco
Description: Effects of flavored tobacco

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-flavored tobacco
Description: Effects of non-flavored tobacco
Study: NCT04200053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology massage
Description: Before the burn dressing, a reflexology massage will be performed for 20 minutes on the right foot and 20 minutes on the left foot. This intervention will continue in the morning for 3 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology massage and passive music
Description: Before the burn dressing, a reflexology massage and passive music will be performed for 20 minutes on the right foot and 20 minutes on the left foot. Instrumental music will be played during the massage. This intervention will continue in the morning for 3 days.
Study: NCT02011282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients will receive daily sessions of electro-neuro-stimulation in the quadriceps muscle for 10 days
Study: NCT02543463

Intervention type: DEVICE
Group type: OTHER
Intervention: Trident X3 Insert with Navigation system

Intervention type: DEVICE
Group type: OTHER
Intervention: Trident X3 Insert with conventional instrumentation
Study: NCT01041482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib 400mg twice daily